Compare Aecom (ACM) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Aecom vs State Street SPDR S&P Biotech ETF — how do they compare? Aecom trades at $62.26 (market cap $8.62B), while State Street SPDR S&P Biotech ETF trades at $159.77. The key difference: Aecom pays a 1.77% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Aecom nearer its low. Which is the better fit depends on your goals.
| ACM | XBI | |
|---|---|---|
Market Cap | $8.62B | — |
Sector | Industrials | Broad Market / Factor |
52-Week High | $134.35 | $164.28 |
52-Week Low | $66.86 | $86.92 |
Enterprise Value | $10.81B | — |
Dividend Yield | 1.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACM's stock is trading at $73.30, down 3.35% in the last session, reflecting negative momentum after a Q2 2026 earnings miss. The technical outlook is bearish, with support at $72 and resistance at $76. Fundamentally, revenue reached $16.14 billion in 2025, but net income margin is thin at 1.87%, and ROE is negative. Recent news includes a securities investigation announcement and a large project charge impacting earnings.
The investment outlook is mixed: analyst consensus is bullish with a $88.25 price target, but risks include earnings volatility, a fraud probe, and rising debt-to-asset ratio. Opportunities lie in record backlog growth and new project wins like the Lisbon airport design. Investors should weigh strong institutional support against operational and legal headwinds.
XBI trades at $159.15, up 0.71% with a bullish technical signal from moving averages. The biotech ETF shows strong momentum with a 17% monthly gain, driven by positive clinical data and M&A activity. Analyst coverage remains limited with a single hold rating, while institutional interest grows with recent $793,000 investment from Bay Colony Advisors.
Outlook remains positive given biotech sector resurgence, though elevated RSI suggests near-term overbought conditions. Key risks include sector volatility and regulatory uncertainty, but AI-driven drug discovery and strong pipeline developments provide growth catalysts for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Aecom
Aecom is one of the largest global providers of design, engineering, construction, and management services. The firm serves a broad spectrum of end markets including infrastructure, water, transportation, and energy. Based in Los Angeles, Aecom has a presence in over 150 countries and employs 51,000. The company generated $13.3 billion in sales and $701 million in adjusted operating income in fiscal 2021.
Read more on ACM →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
